Member Info for Mavern

Kapkina - I always hesitate to make 12 month share price predictions but, since you asked, minimum £3 but possibly as high as £10. FDA approval, and the lead up to it, should cause a significant re-rate. Justin Waite sees it x 100 in a few years. This seems a little too optimistic to me but even if he’s only 10% right I think we’ll all be happy with that

This is the only share I’ve ever owned where I don’t get concerned about any drops in the share price, it’s all part of periodic consolidation within the inevitable journey up. Where that journey ends is anyone’s guess but I certainly concur it’s many multiples of where we are today. Game changing technology, no competition, FDA approval shortly with minimal risk, Hatch Waxman 5 year exclusivity, growing demand unfortunately due to long covid. Risk/reward almost entirely skewed on the side of reward.

With FDA approval now less than 4 months away I’m really surprised we are not at least £1.50 by now. Those invested in NSCI have seen this week that the market can apply irrational valuations and then suddenly a catalyst comes along that creates a sudden re-rate. POL’s technology is game changing in the field of taking 40 year old pulmonary MRI technology to the next level and sadly the prevalence of long covid has/will make the global market even bigger. With no competition and possibility of “hatch waxman” 5 year exclusivity in the US the potential here is off the scale.

V O X Podcast Interview with CEO Richard Hullihen came out late yesterday afternoon. Sorry, if I attach a link it will be blanked out as LSE seems to forbid the word V O X! ... but it’s easily found. Interesting to hear the numerous possibilities for this technology beyond just pulmonary. The potential is staggering.

It’s not on until 5.30pm

Know0 - I’m also pretty sure there will not be a placing. My scenario was hypothetical, hence the inclusion of the words “Even if”. Everything is pointing to alternative short term financing which should not be difficult to acquire.

Absolutely agree toptuf. I also think a placing is already priced in, probably twice over. Once on the day of the RNS and then once again thereafter. Even if there was a placing I doubt if it would be much below where the share price is currently, and dilution would probably be minimal as it’s probably not a huge sum. So under any scenario confirmation of ANY form of financing should be a catalyst to drive the share price well up

Same Jonners, still clutching a straws. 200 negative posts since share price was 1.9p in 2019

Very upbeat analysis with lots of potential re-rate catalysts and pending news. Looks very oversold at this level.

Very reassuring to hear Polarean have had an “orientation meeting” with the FDA, part of which was presenting the detail of all the experimental equipment they already have out in the market, and that it went “very successfully”.

At present mid 40’s is looking more likely than mid 30’s DJG

I think it speaks volumes for the strength and resilience of RMM as an investment proposition that after the recent run of success we still only have ONE resident troll, Sam Smithers. Having invested for many years, and read these boards for many years, I can categorically state this is highly unusual

Sorry I should know by now that LSE doesn’t allow V O X links, but it’s easily found :-)

More coverage for Polarean on Friday afternoons V O X podcast. Once again, very upbeat. Paul Hill, their guest full-time investor and equity analyst, commented that if Polarean is granted FDA approval early October “it will become the perfect acquisition target and will be taken out within a year by the MRI big players”. Coverage is from 59m 35s to 1hr 3m 50s https://www.**********.co.uk/articles/tekcapital-i3-energy-blue-star-capital-and-paul-hill-270c49e/

The story for RMM still remains very much intact. Given the turnaround plan in place some delays were inevitable. It currently has the valuation of a junior explorer, and yes it has those assets too, including gold. But you also get a “soon to go into production” copper mine thrown in for free at a time when the world is seriously short of supply. Markets are forward looking and this will re-rate significantly. Friday’s small setback creates a great entry point.

GTMUFO: “remember here if copper was not at the price it is today rmm would be dead in sea” ... On what basis do you conclude this? RMM can be highly profitable at copper prices WAY below where they are today! Evidence of this is in the forward hedged sales nearer to $ 3.00 per Ib

I’ve also added more yesterday. It’s looking increasingly evident that SAV are navigating their way through the public consultation process in a very diligent manner. This, in addition to the connections and influence Galp surely have, is quite reassuring

Here’s a link to the Justin Waite weekend podcast. Polarean covered from 22m to 30m https://audioboom.com/posts/7856540-the-weekend-podcast

Chart technicals are almost irrelevant when a company undergoes a serious re-rate once approaching a key news event. Possibly that’s why serious investors are taking positions now. Waiting for the RSI to normalise could be counter productive in this particular case. As I mentioned earlier, any recent pullbacks have been minuscule.

Bracco are the leading contender should there be a takeover approach. They did the same with Blue Earth Diagnostics and this is playing out in a similar way ie. with their “strategic investment” in March 2020 and inclusion on the Board. Hope it’s not too soon though as this has much further to run.